Unlock instant, AI-driven research and patent intelligence for your innovation.

Benzamide compound

A compound and formamide technology, applied in the field of benzamide compounds, can solve problems such as undisclosed compounds, and achieve the effect of inhibiting overeating

Inactive Publication Date: 2012-09-05
ASTELLAS PHARMA INC
View PDF30 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the compounds of the present invention are not specifically disclosed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Benzamide compound
  • Benzamide compound
  • Benzamide compound

Examples

Experimental program
Comparison scheme
Effect test

manufacture example 1

[0181] 3-Hydroxy-5-isopropoxy-N-(1-methyl-1H-pyrazol-3-yl)benzamide (492mg), potassium carbonate (445mg), N-methylpyrrolidone A solution of 5-chloropyrazine-2-carbonitrile in NMP (3 mL) was added to a mixture of (NMP) (4 mL), followed by stirring at room temperature for 4 hours and at 50° C. for 20 minutes. Diethyl ether (20 mL) and water (20 mL) were added for liquid separation, the organic layer was washed with water (20 mL) and saturated brine (20 mL) successively, and the aqueous layer was extracted with diethyl ether (20 mL) again. The combined organic layers were dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane-ethyl acetate=1:1~1:2) to obtain 3-[(5-cyanopyrazin-2-yl)oxy]-5 in the form of light yellow oil - Isopropoxy-N-(1-methyl-1H-pyrazol-3-yl)benzamide (632 mg).

manufacture example 2

[0183] 3-[(5-cyanopyrazin-2-yl)oxy]-5-isopropoxy-N-(1-methyl-1H-pyrazol-3-yl)benzamide under ice cooling (615 mg) in methanol (5 mL) was added with 50% aqueous hydroxylamine solution (200 μL), followed by stirring at room temperature for 1 hour. Water (5 mL) was added, and the insoluble material was filtered off and washed with methanol. Drying under reduced pressure gave 3-{[5-(N'-hydroxycarboxamidinyl)pyrazin-2-yl]oxy}-5-isopropoxy-N-(1-methyl- 1H-pyrazol-3-yl)benzamide (618 mg).

manufacture example 3

[0185] 3-{[5-(N'-hydroxycarboxamidinyl)pyrazin-2-yl]oxy}-5-isopropoxy-N-(1-methyl-1H-pyrazol-3-yl ) benzamide (316 mg) was suspended in a mixed solvent of dioxane (2 mL)-chloroform (2 mL), and triethylamine (260 μL), ethyl chloro(oxo)acetate ( 120 μL), and stirred at room temperature for 45 minutes and at 80° C. for 4 hours. The reaction mixture was cooled to room temperature, and triethylamine (64 µL) and ethyl chloro(oxo)acetate (30 µL) were added thereto, followed by stirring at 80°C for 2 hours and at 100°C for 1 hour. The reaction mixture was cooled to room temperature, ethyl acetate and water were added for liquid separation, the organic layer was washed successively with saturated aqueous sodium bicarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (n-hexane-ethyl acetate=1:1~1:2) to obtain 3-(5-{3-isopropoxy-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

Disclosed is a compound which is useful as a GK activator. Studies have been made on compounds which have a GK activating action and are therefore promising as active ingredients of pharmaceutical compositions for the treatment of diabetes, type 2 diabetes, obesity, metabolic syndrome and diseases associated with the aforementioned diseases, and it is confirmed that a specific benzamide compound has an excellent GK activating action. The benzamide compound has a GK activating action and can be used as a prophylactic and / or therapeutic agent for diabetes, type 2 diabetes, obesity, metabolic syndrome and diseases associated with the aforementioned diseases.

Description

technical field [0001] The present invention relates to a benzamide compound useful as an active ingredient of a pharmaceutical composition, for example, a pharmaceutical composition for treating diabetes. Background technique [0002] GK (Glucokinase (ATP: D-hexose 6-phosphotransferase, EC2.7.1.1)) is an enzyme that phosphorylates six carbon sugars expressed in the pancreas and liver. exist. This enzyme belongs to the hexokinase family and is also known by the alias hexokinase IV. Compared with other hexokinases, GK has the following characteristics: 1) It has a low affinity for glucose as a substrate, showing a Km value close to the blood glucose concentration, 2) it is not affected by glucose-6- Inhibition of phosphoric acid, 3) The molecular weight is about half of 50kDa; etc. The human glucokinase gene is located on chromosome 7 7p13 in the form of a single gene, which is regulated by different tissue-specific promoters more than 30kb apart in pancreatic β cells and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D213/75A61K31/415A61K31/4155A61K31/4245A61K31/426A61K31/433A61K31/44A61K31/4439A61K31/455A61K31/4965A61K31/497A61K31/506A61K31/5377A61P3/00A61P3/04A61P3/10A61P9/00A61P9/08A61P9/10A61P13/12A61P25/00A61P27/02A61P43/00C07D213/80C07D231/40C07D241/20C07D277/20C07D277/46C07D285/08C07D401/14C07D403/12C07D403/14C07D405/12C07D405/14C07D409/14C07D413/12C07D413/14
CPCA61P3/00A61P3/04A61P3/06A61P3/10A61P9/00A61P9/08A61P9/10A61P13/12A61P25/00A61P27/02A61P43/00C07D213/75C07D213/80C07D231/40C07D241/20C07D277/20C07D277/46C07D285/08C07D401/14C07D403/12C07D403/14C07D405/12C07D405/14C07D409/14C07D413/12C07D413/14A61K31/497
Inventor 早川昌彦吉村诚司流石大辅小池贵德二川原充启奥村光晶槙圭介
Owner ASTELLAS PHARMA INC